Close

pCDCAR1 CD20 h(FcγRIII) (CAR-MZ055)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of NK cells to target human CD20. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to FcγRIII signaling domains. And the vector product was designed for the treatment of Chronic lymphocytic leukemia (CLL).

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD20
  • Targeting Cell Type
  • NK cell
  • Targeting Diseases
  • Chronic lymphocytic leukemia (CLL)
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-FcγRIII
  • Discription of Signaling Cassetes
  • FcγR
    Fc-gamma receptors (FcγR) are Fc receptors (abbreviated FcR) for antibody IgG. All of the Fcγ receptors (FcγR) belong to the immunoglobulin superfamily and are the most important Fc receptors for inducing phagocytosis of opsonized (marked) microbes. This family includes several members, FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), FcγRIIIB (CD16b), which differ in their antibody affinities due to their different molecular structure.

Target

  • Clone
  • Ofatumumab
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • membrane spanning 4-domains A1
  • Synonyms
  • B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; BA0185

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
FCM

Fig.1 Recognition of truncations of CD20 by Rituximab and Ofatumumab.

CAR Construction : Latest CAR Construction

Fig.1 Recognition of truncations of CD20 by Rituximab and Ofatumumab.

Cyt

Fig.2 Aptoptosis (as a percentage of expressing cells) upon expression and upon activation by Ofatumumab in the different test constructs.

CAR Construction : Latest CAR Construction

Fig.2 Aptoptosis (as a percentage of expressing cells) upon expression and upon activation by Ofatumumab in the different test constructs.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD20 (Ofatumumab) h(FcγRIII) CAR, pCDCAR1 (CAR-MZ055). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.